Loading...
•
Mar 31
Aytu BioScience Q3 2025 Earnings Report
Aytu BioPharma reported strong revenue growth and turned a profit in Q3 2025.
Key Takeaways
Aytu BioPharma achieved 32% revenue growth year-over-year in Q3 2025, driven by robust performance in both its ADHD and Pediatric portfolios. The company reported net income of $4.0 million and adjusted EBITDA of $3.9 million, reflecting successful execution of its strategic realignment and cost optimization efforts.
Total revenue grew 32% year-over-year to $18.5 million.
Net income reached $4.0 million, compared to a $2.9 million loss in the prior year period.
The ADHD Portfolio contributed $15.4 million in revenue, growing 25% year-over-year.
Cash and cash equivalents stood at $18.2 million at quarter-end after debt repayments.
Aytu BioScience
Aytu BioScience
Forward Guidance
The company will continue focusing on expanding its prescription portfolio and leveraging operational efficiencies to drive profitability and cash flow.
Positive Outlook
- Ongoing growth in ADHD and Pediatric portfolios.
- Streamlined operations reduced operating expenses by 13% YoY.
- Continued paydown of long-term debt.
- Expanded utilization of Aytu RxConnect platform.
- Positioned for positive cash flow generation.
Challenges Ahead
- Gross margin decreased to 69% due to temporary inventory costs.
- ADHD portfolio margins impacted by production transition.
- Revenue still concentrated in two main therapeutic areas.
- Limited revenue contribution from other or discontinued products.
- Ongoing dependence on third-party manufacturing and supply chain.